Floatz logo

Imm-6-415

Advanced Solid Tumor (Phase 1)

Immuneering CorporationPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

9 Active assets in the Advanced Solid Tumor (Phase 1) cohort.

Asset / SponsorPhaseRating
Nhwd-870
Zhejiang Wenda Pharma Technology LTD.
Phase 2CCC
Pembrolizumab
Aptabio Therapeutics, Inc.
Phase 1CC
Epirubicin
Aptabio Therapeutics, Inc.
Phase 1CC
ep102
Epics Therapeutics
Phase 1CC
Apx-343A
Aptabio Therapeutics, Inc.
Phase 1CC

View all 9 →

Same molecule, other indications

Imm-6-415 is also rated in:

cutaneous melanomaDormant
CCC
Indicative ·
52 / 100
View asset →
pancreatic adenocarcinomaDormant
CCC
Indicative ·
50 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →